Overview
CBIO market data
Price History
CBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.97 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.72 – $27.41 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $585.1 · P/B 0.81 · P/S 49.24.
Company news
8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)SEC EDGAR · Jul 15, 2026, 8:58 PM
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobenewswire Inc · Jul 15, 2026, 11:15 AM
Reported Earlier, Crescent Biopharma Prices Public Offering Of 8,094,793 Ordinary Shares At $14.50 Per Share, Expects $125.0M In Gross ProceedsBenzinga · Jul 15, 2026, 7:08 AM
Crescent Biopharma shares are trading lower after the company announced a proposed public offering.Benzinga · Jul 14, 2026, 8:04 PM
Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms UndisclosedBenzinga · Jul 14, 2026, 8:02 PM
Crescent Biopharma Files Prospectus For Offering $500M Mixed ShelfBenzinga · Jul 1, 2026, 8:25 PM
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For MondayBenzinga · Jun 1, 2026, 12:57 PM
HC Wainwright & Co. Downgrades Crescent Biopharma to NeutralBenzinga · Jun 1, 2026, 11:33 AM
Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027Benzinga · May 21, 2026, 9:45 PM